Stock Track | Moderna Soars 5.05% on FDA Application for New COVID-19 Variant Vaccine

Stock Track
05-27

Moderna, Inc. (MRNA) shares surged 5.05% in pre-market trading on Tuesday, following the company's announcement of a significant regulatory development. The biotechnology firm has filed an application with the U.S. Food and Drug Administration (FDA) for the review of its Spikevax formula, which targets the SARS-CoV-2 variant LP.8.1.

This move demonstrates Moderna's continued efforts to adapt its COVID-19 vaccine to emerging variants, potentially positioning the company to maintain its strong market presence in the ongoing fight against the pandemic. The positive market reaction suggests investors are optimistic about the potential approval and subsequent demand for this updated vaccine formulation.

Adding to the positive sentiment, Moderna also announced its upcoming participation in two major healthcare conferences. The company will present at the Jefferies Global Health Care Conference on June 5th and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11th. These high-profile appearances provide Moderna with platforms to showcase its latest developments and future strategies, potentially further boosting investor confidence.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10